Kinnate Biopharma focuses on developing small molecule kinase inhibitors that treat cancers based on genomic profiles. Its portfolio includes KIN-2787, KIN-3248, and Cyclin-Dependent Kinase 12(CDK12) inhibitors. The company was established in San Francisco in 2018 as a former subsidiary of Fount Therapeutics.